With an initial focus on exosome biology, the technology giant is looking for ways to use the microfluidic chip, which can sort particles as small as 20 nanometers.
The QIAseq panels, which are available now, are the first of three major product launches Qiagen has planned for the second half of the year.
The company has raised venture funding to support commercialization of a variety of blood-based cancer assays in Taiwan, but has yet to publish data validating its approach.
Longhorn Vaccines and Diagnostics' one-step reagent for sample collection and transport enhanced M. tuberculosis detection on the Xpert MTB/RIF assay.
The automated device was able to detect pathogens from clinical samples and can be built from a 3D printer retailing at $750 or less.
The aim of the project, called Metafluidics, is to replace cumbersome conventional approaches with a cheaper, faster, and higher-throughput microfluidics platform.
By modifying a library construction method, researchers were able to analyze tiny amounts of small RNAs.
The device, the ORAcollectDx, is an alternative to buccal swabs and provides higher DNA yields, according to the firm.
Last month, the companies announced that Takara Bio USA — formerly Clontech Laboratories and now a subsidiary of Japan's Takara Bio — would acquire WaferGen.
At a user meeting in London this week, Chief Technology Officer Clive Brown introduced the SmidgIon and a number of other technology developments, as well as a new synthetic biology spinoff.
The company will use proceeds from the placement to conduct clinical trials on its Parsortix CTC system, which has been adopted by Cancer Research UK's Mancherster Institute.
The company said instrument sales rose 41 percent during the quarter, while sales of consumables rose 11 percent.
Thermo Fisher Scientific has developed forensics panels to run on its S5 sequencing system in anticipation that the forensics market will slowly move from CE to NGS.
The company said it will use the funds to commercialize its products for automated preparation of genomic and genetic testing samples.
The programmable nuclease can replace restriction enzymes, enables cloning of large genomic sequences, and can deplete unwanted DNA species.
The firm said it has addressed the doublet issue for its C1 analyzer, and noted that it expects the bulk of revenue growth to come in the second half of the year.
Over the next half year, iGenomX plans to roll out its sequencing library prep chemistry for linked read sequencing.
Through the acquisition, Miroculus will be able to automate and simplify the detection of miRNAs from blood using Kapplex's digital microfluidic technology.
The UK-based firm plans to marry its core strengths with the probes and PCR platforms, and to build its sales force in the US.
Both companies are working together to market both companies' technology for long-read DNA sequencing.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.